Understanding how glioblastoma brain cancer becomes resistant to radiation treatment
Targeting Adaptive Radioresistance of Glioblastoma
This study is looking into how glioblastoma, a tough type of brain cancer, manages to survive radiation treatment, with the hope of finding new ways to make the treatment more effective for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11013836 on NIH RePORTER |
What this research studies
This research investigates the mechanisms that allow glioblastoma, a deadly brain cancer, to survive radiation therapy. By developing advanced models that mimic the genetic diversity of glioblastoma, including its stem cells, the research aims to uncover why some cancer cells resist treatment. The study employs innovative techniques like CRISPR screening to identify genes associated with radioresistance, potentially leading to new therapies that can overcome this challenge. Patients may benefit from insights that could improve treatment strategies for glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma, particularly those who have undergone radiation therapy.
Not a fit: Patients with other types of brain tumors or those who have not received radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting radioresistance in cancer, but this specific approach focusing on glioblastoma and its stem cells is relatively novel.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Osuka, Satoru — University of Alabama at Birmingham
- Study coordinator: Osuka, Satoru
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.